Dr Li on Frontline Treatment Considerations With IO-Based Combinations in Unresectable HCC
November 15th 2023Daneng Li, MD, discusses considerations when choosing between treatment with immuno-oncology-based combination regimens or single-agent TKIs in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma, highlighting which patient and disease factors influence these decisions.
Dr Stein on Key Considerations When Selecting an Immunotherapy Approach in HCC
October 10th 2023Stacey Stein, MD, discusses key considerations when selecting a first-line treatment approach for higher-risk patients with hepatocellular carcinoma, and in what scenarios the combination of atezolizumab and bevacizumab is a viable approach in this population.